Volume 20, Number 3—March 2014
CME ACTIVITY - Research
Use of Drug-Susceptibility Testing for Management of Drug-Resistant Tuberculosis, Thailand, 2004–2008
Eugene Lam, Sriprapa Nateniyom, Sara Whitehead, Amornrat Anuwatnonthakate, Patama Monkongdee, Apiratee Kanphukiew, Jiraphan Inyaphong, Wanlaya Sitti, Navarat Chiengsorn, Saiyud Moolphate, Suporn Kavinum, Narin Suriyon, Pranom Limsomboon, Junya Danyutapolchai, Chalinthorn Sinthuwattanawibool, and Laura Jean Podewils
Table 2
Baseline clinical characteristics for patients with drug-resistant TB, Thailand, 2004–2008*
| Characteristic | No. (%) patients with |
Patients with RIF-resistant vs. MDR TB, p value‡ | ||||||
|---|---|---|---|---|---|---|---|---|
| RIF-resistant TB, n = 121 |
MDR TB, n = 369 |
|||||||
| Included, n = 36 | Excluded, n = 85 | P value† | Included, n = 172 | Excluded, n = 197 | P value† | |||
| Case status | ||||||||
| New | 26 (72.2) | 56 (65.9) | 0.64 | 89 (51.7) | 95 (48.2) | 0.51 | 0.17 | |
| Retreatment after relapse | 6 (16.7) | 19 (22.4) | 25 (14.5) | 24 (12.2) | ||||
| Retreatment after failure | 2 (5.6) | 1 (1.2) | 21 (12.2) | 19 (9.6) | ||||
| Retreatment after default | 1 (2.8) | 4 (4.7) | 14 (8.1) | 18 (9.1) | ||||
| Transfer in | 0 (0.0) | 1 (1.2) | 10 (5.8) | 16 (8.1) | ||||
| Other |
1 (2.8) |
4 (4.7) |
13 (7.6) |
25 (12.7) |
||||
| Site of TB | ||||||||
| Pulmonary | 33 (91.7) | 61 (71.8) | 0.05 | 160 (93.0) | 162 (82.2) | 0.008 | 0.69 | |
| Extrapulmonary | 2 (5.6) | 13 (15.3) | 5 (2.9) | 15 (7.6) | ||||
| Both |
1 (2.8) |
11 (12.9) |
7 (4.1) |
20 (10.2) |
||||
| Cough >2 wk | ||||||||
| No | 11 (30.6) | 39 (45.9) | 0.22 | 40 (23.3) | 61 (31.0) | <0.001 | 0.36 | |
| Yes | 25 (69.4) | 45 (52.9) | 132 (76.7) | 123 (62.4) | ||||
| Data missing |
0 (0.0) |
1 (1.2) |
0 (0.0) |
13 (6.6) |
||||
| Smear status | ||||||||
| Negative | 4 (11.1) | 11 (12.9) | 0.44 | 26 (15.1) | 26 (13.2) | 0.57 | 0.71 | |
| Positive | 30 (83.3) | 63 (74.1) | 140 (81.4) | 160 (81.2) | ||||
| Data missing |
2 (5.6) |
11 (12.9) |
6 (3.5) |
11 (5.6) |
||||
| Chest radiograph | ||||||||
| Normal | 0 (0.0) | 4 (4.7) | 0.27 | 4 (2.3) | 10 (5.1) | 0.17 | 0.79 | |
| Abnormal, no cavity | 22 (61.1) | 41 (48.2) | 109 (63.4) | 104 (52.8) | ||||
| Abnormal, with cavity | 8 (22.2) | 29 (34.1) | 34 (19.8) | 48 (24.4) | ||||
| Data missing |
6 (16.7) |
11 (12.9) |
25 (14.5) |
35 (17.8) |
||||
| HIV status | ||||||||
| Negative | 23 (63.9) | 29 (34.1) | 0.004 | 112 (65.1) | 92 (46.7) | 0.001 | 0.17 | |
| Positive | 13 (36.1) | 46 (54.1) | 47 (27.3) | 75 (38.1) | ||||
| Data missing |
0 (0.0) |
10 (11.8) |
13 (7.6) |
30 (15.2) |
||||
| Outcome | ||||||||
| Treatment success | ||||||||
| TB cured | 20 (55.6) | 26 (30.6) | 0.25 | 51 (29.7) | 33 (16.8) | 0.06 | 0.07 | |
| Treatment completed | 5 (13.9) | 21 (24.7) | 25 (14.5) | 36 (18.3) | ||||
| Poor outcome | ||||||||
| Treatment failed | 1 (2.8) | 5 (5.9) | 31 (18.0) | 29 (14.7) | ||||
| Patient defaulted | 3 (8.3) | 10 (11.8) | 17 (9.9) | 28 (14.2) | ||||
| Patient died | 5 (13.9) | 12 (14.1) | 30 (17.4) | 40 (20.3) | ||||
| Transferred out | 2 (5.6) | 9 (10.6) | 15 (8.7) | 23 (11.7) | ||||
| Ongoing treatment | 0 | 2 (2.4) | 3 (1.7) | 8 (4.1) | ||||
*Patients were from the Thailand TB Active Surveillance Network and were either included or not included in the current study. TB, tuberculosis; RIF, rifampin; MDR, multidrug-resistance.
†p values reflect comparison between included and excluded patients in each TB drug resistance group.
‡p values reflect comparison between included RIF-resistant and MDR TB patients.
Page created: February 25, 2014
Page updated: February 25, 2014
Page reviewed: February 25, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.